BRITISH COLUMBIA, Canada, Sept. 8 /PRNewswire-FirstCall/ -- InNexus
Biotechnology Inc. (TSX: IXS.V; OTC Bulletin Board: IXSBF)
(http://www.ixsbio.com), a drug development company commercializing the next
generation of monoclonal antibodies based on its Dynamic Cross Linking
(DXL(TM)) technology, announces Jeff Morhet, CEO and Chairman, to present
during the Wall Street Analyst Forum at the University Club in New York City,
Wednesday, September 10, 2008.
CEO and Chairman, Jeff Morhet will provide a company overview, including
information about InNexus' unique business strategy, its DXL(TM) technology
platform and upcoming company milestones. Investors, venture capitalists,
company executives, scientists and other industry leaders will attend the
conferences.
The Wall Street Analyst Forum has been a sponsor of annual analyst
conferences for NYSE/NASDAQ/AMEX corporations in New York, Boston and London
since 1988. The conferences support participating companies by inviting all
buy/sell side analyst and portfolio managers to attend while leveraging the
use of three new media channels. Over 2,500 public corporations have
presented ranging from General Electric, Nokia, Pfizer, Motorola, Inc.,
Unilever, KB Homes to Adobe Systems.
A live web cast is also available to view online at
http://wsw.com/webcast/wsaf7/. Mr. Morhet will be presenting from 9:50-10:30
AM EDT on Wednesday, September 10th.
About InNexus
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL(TM) technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL(TM) antibodies utilize unique, novel and patented methods
and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, which may cause
actual results or performance to differ materially from those currently
anticipated in such statements.
SOURCE InNexus Biotechnology Inc.